SCHEMBL24257553

SCHEMBL24257553

Cc1c(-c2cccc(Cl)c2)cnc(C(=O)NC2(C(=O)O)CCC2)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.46
FABP4 P15090 6/20 0.44
FABP5 Q01469 3/20 0.42
VEGFA P15692 3/20 0.40
FLT1 P17948 3/20 0.40
EGLN3 Q9H6Z9 3/20 0.40
TET3 O43151 1/20 0.40
BBOX1 O75936 1/20 0.40
ASPH Q12797 1/20 0.40
TET2 Q6N021 1/20 0.40
KDM8 Q8N371 1/20 0.40
OGFOD1 Q8N543 1/20 0.40
TET1 Q8NFU7 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
LPAR1 Q92633 1/20 0.40
PTGFR P43088 1/20 0.38
ERAP1 Q9NZ08 2/20 0.38
FPR2 P25090 1/20 0.38
GRM5 P41594 1/20 0.38
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257591 0.96 EGLN1 (0.49) EGLN1FABP4FABP5VEGFAFLT1
SCHEMBL30546863 0.90 EGLN1 (0.41) EGLN1FABP4VEGFAFLT1EGLN3
SCHEMBL24257523 0.90 EGLN1 (0.41) EGLN1FABP4VEGFAFLT1EGLN3
SCHEMBL24257556 0.89 EGLN1 (0.41) EGLN1FABP4FABP5VEGFAFLT1
SCHEMBL30546850 0.83 EGLN1 (0.41) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257529 0.83 EGLN1 (0.41) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL30546845 0.82 EGLN1 (0.41) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257527 0.82 EGLN1 (0.41) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL26260456 0.79 PIN1 (0.50) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24257633 0.78 EGLN1 (0.65) EGLN1VEGFAFLT1EGLN3TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 EGLN1 19/4885FABP4 4373/4885FABP5 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.